2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel.

[1]  R. Golub,et al.  Economic Analysis of Granulocyte Colony Stimulating Factor as Adjunct Therapy for Older Patients with Acute Myelogenous Leukemia (AML): Estimates from a Southwest Oncology Group Clinical Trial , 2001, Cancer investigation.

[2]  Shaun Parsons,et al.  Growth factor practice patterns among pediatric oncologists: results of a 1998 Pediatric Oncology Group Survey. Economic Evaluation Working Group the Pediatric Oncology Group. , 2000, Journal of pediatric hematology/oncology.

[3]  S. Martino,et al.  Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. , 2000, The New England journal of medicine.

[4]  A. Nademanee,et al.  Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. , 2000, Blood.

[5]  E. Solary,et al.  Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Terry L. Smith,et al.  Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. , 2000, Journal of the National Cancer Institute.

[7]  C. Bennett,et al.  Cost Analyses of Adjunct Colony Stimulating Factors for Acute Leukemia: Can They Improve Clinical Decision Making , 2000, Leukemia & lymphoma.

[8]  D. Girling,et al.  Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  K. Schulman,et al.  Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  L. Gordon,et al.  A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: analysis of response, toxicity, and dose intensity. , 1999, Blood.

[11]  J. Zalcberg,et al.  Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumors. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  P. Adams,et al.  NCCN practice guidelines for fever and neutropenia , 1999 .

[13]  A. Santoro,et al.  Dose-escalation of CHOP in non-Hodgkin's lymphoma. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  M. Millward,et al.  Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: a randomized, crossover comparison. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  H. Lazarus,et al.  Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Christian Jacques,et al.  Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer , 1998, The Lancet.

[17]  J. Ritz,et al.  Efficacy and costs of granulocyte colony-stimulating factor in allogeneic T-cell depleted bone marrow transplantation. , 1998, Blood.

[18]  A. Ravaud,et al.  Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  I. Tannock,et al.  Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Edward J. Lee,et al.  A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. , 1998, Blood.

[21]  J. Peterse,et al.  Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement , 1998, The Lancet.

[22]  M. Mazumdar,et al.  Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Crowley,et al.  Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Smink,et al.  Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  F. Appelbaum,et al.  A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). , 1998, Blood.

[26]  B. Redman,et al.  Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  C. Colby,et al.  Early vs delayed administration of G-CSF following autologous peripheral blood stem cell transplantation , 1998, Bone Marrow Transplantation.

[28]  N. Schmitz,et al.  Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation , 1998, Bone Marrow Transplantation.

[29]  P. Hurteloup,et al.  A Placebo-Controlled Study of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor Administered During and After Induction Treatment for De Novo Acute Myelogenous Leukemia in Elderly Patients , 1998 .

[30]  S. Saxman,et al.  Primary salvage treatment of recurrent germ cell tumors: experience at Indiana University. , 1998, Seminars in oncology.

[31]  A. Tabilio,et al.  CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF , 1998, Bone Marrow Transplantation.

[32]  L. Collette,et al.  Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  B. Meisenberg,et al.  A combination of low‐dose cyclophosphamide and colony‐stimulating factors is more cost‐effective than granulocyte‐colony‐stimulating factors alone in mobilizing peripheral blood stem and progenitor cells , 1998, Transfusion.

[34]  J. Shuster,et al.  Randomized trial of r-metHu granulocyte colony-stimulating factor in an intensive treatment for T-cell leukemia and advanced-stage lymphoblastic lymphoma of childhood: a Pediatric Oncology Group pilot study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. Verweij,et al.  Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  B. McAneny,et al.  Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim , 1998, British journal of haematology.

[37]  B. Overmoyer,et al.  Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trial , 1998, Bone Marrow Transplantation.

[38]  N. Robert,et al.  A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression. , 1998, Cancer investigation.

[39]  M. Kahn,et al.  Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  J. Biggs,et al.  A randomised, blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for haemopoietic stem cell mobilisation in patients with severe active rheumatoid arthritis , 1998, Bone Marrow Transplantation.

[41]  A. Ganser,et al.  A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Filgrastim in Remission Induction and Consolidation Therapy for Adults With De Novo Acute Myeloid Leukemia , 1997 .

[42]  K. Sullivan,et al.  Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. , 1997, Blood.

[43]  M A Boogaerts,et al.  Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  D. Winfield,et al.  G‐CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial , 1997, British journal of haematology.

[45]  J. Wagner,et al.  Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF. , 1997, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[46]  L. Young,et al.  1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[47]  F. Stewart,et al.  Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  U. Jaeger,et al.  Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia--a randomized phase-III study. , 1997, Blood.

[49]  P. Pedrazzoli,et al.  Role of tumor cells contaminating the graft in breast cancer recurrence after high-dose chemotherapy , 1997, Bone Marrow Transplantation.

[50]  T. Habermann,et al.  Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. , 1997, The New England journal of medicine.

[51]  M. Relling,et al.  Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. , 1997, The New England journal of medicine.

[52]  J. V. Von Roenn,et al.  Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. , 1997, The New England journal of medicine.

[53]  R. Stahel,et al.  Randomized trial showing equivalent efficacy of filgrastim 5 micrograms/kg/d and 10 micrograms/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  J. Armitage,et al.  Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  J. Doroshow,et al.  Effect of CD34 " Selection and Various Schedules of Stem Cell Reinfusion and Granulocyte Colony-Stimulating Factor Priming on Hematopoietic Recovery After High-Dose Chemotherapy for Breast Cancer , 1997 .

[56]  M. Stevens,et al.  Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  G. Fountzilas,et al.  Paclitaxel and carboplatin in recurrent or metastatic head and neck cancer: a phase II study. , 1997, Seminars in oncology.

[58]  L. Saltz,et al.  Topotecan and the treatment of recurrent ovarian cancer: is there a role for granulocyte colony-stimulating factor? , 1997, Seminars in oncology.

[59]  G. Scagliotti,et al.  Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  R. Golub,et al.  Economic analyses of phase III cooperative cancer group clinical trials: are they feasible? , 1997, Cancer investigation.

[61]  Natale Rb.  Preliminary results of a phase I/II clinical trial of paclitaxel and carboplatin in non-small cell lung cancer , 1996 .

[62]  A. Ho,et al.  Pluripotent and lineage-committed CD34+ subsets in leukapheresis products mobilized by G-CSF, GM-CSF vs. a combination of both. , 1996, Experimental hematology.

[63]  J. Wagstaff,et al.  Continuous infusion or subcutaneous injection of granulocyte-macrophage colony-stimulating factor: increased efficacy and reduced toxicity when given subcutaneously. , 1996, British Journal of Cancer.

[64]  M. Somerfield,et al.  Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. The Health Services Research Committee of the American Society of Clinical Oncology. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  E. Partridge,et al.  Comparison of combination therapy with paclitaxel Taxol® and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group study , 1996, International Journal of Gynecologic Cancer.

[66]  F. Mandelli,et al.  Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  R. Ozols,et al.  Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  K. Gelmon,et al.  Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  M. Schrappe,et al.  A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group. , 1996, Blood.

[70]  N. Schmitz,et al.  Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients , 1996, The Lancet.

[71]  J. Blay,et al.  Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  H. Keizer,et al.  Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  C. Hudis,et al.  Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  E. Anaissie,et al.  Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia. , 1996, The American journal of medicine.

[75]  E. Vellenga,et al.  An economic model to assess the savings from a clinical application of haematopoietic growth factors. , 1996, European journal of cancer.

[76]  A. Roberts,et al.  Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. , 1995, Blood.

[77]  D. Neuberg,et al.  High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  A. Caraceni,et al.  Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  T. Lipp,et al.  Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial. , 1995, Blood.

[80]  J. Bennett,et al.  A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). , 1995, Blood.

[81]  J. Crowley,et al.  Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  W. Evans,et al.  Pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in children after intravenous and subcutaneous administration. , 1995, Journal of pharmaceutical sciences.

[83]  Stephen L. George,et al.  Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia , 1995 .

[84]  R. Bouabdallah,et al.  A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. , 1995, The New England journal of medicine.

[85]  J. Mayordomo,et al.  Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. , 1995, Journal of the National Cancer Institute.

[86]  D. Huhn,et al.  Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  E. Pearlman,et al.  Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  J. Singer,et al.  Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. , 1995, Bone marrow transplantation.

[89]  S. Stewart,et al.  Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  R. Storb,et al.  Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor , 1995 .

[91]  A. Deisseroth,et al.  Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts , 1995 .

[92]  N. Schmitz,et al.  Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor) , 1995, Blood.

[93]  N. Schmitz,et al.  Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. , 1995, Bone marrow transplantation.

[94]  R. Fisher,et al.  Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  T M Grogan,et al.  Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  Max Wolf,et al.  Filgrastim in Patients with Chemotherapy-Induced Febrile Neutropenia: A Double-Blind, Placebo-Controlled Trial , 1994, Annals of Internal Medicine.

[97]  M. Murata,et al.  Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non‐Hodgkin's lymphoma , 1994, Cancer.

[98]  A. Nademanee,et al.  High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  N. Schmitz,et al.  G‐CSF‐mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft , 1994, British journal of haematology.

[100]  L. Norton,et al.  Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. , 1994, The New England journal of medicine.

[101]  Masahiro Yoshida,et al.  A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group [see comments] , 1994 .

[102]  A. Mäkipernaa,et al.  Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. , 1994, The Pediatric infectious disease journal.

[103]  L. Kanz,et al.  Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors [see comments] , 1994 .

[104]  R. Finberg,et al.  Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  L. Kanz,et al.  Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. , 1994, Blood.

[106]  M. Andreeff,et al.  Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. , 1993, The New England journal of medicine.

[107]  J. Minna,et al.  Limited stage small cell lung cancer treated with concurrent hyperfractionated chest radiotherapy and etoposide/cisplatin , 1993 .

[108]  J. Crowley,et al.  An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  Donnelly Jp.  Selective decontamination of the digestive tract and its role in antimicrobial prophylaxis , 1993 .

[110]  R. Benjamin,et al.  Outpatient treatment of febrile episodes in low‐risk neutropenic patients with cancer , 1993, Cancer.

[111]  P. Pizzo,et al.  Management of fever in patients with cancer and treatment-induced neutropenia. , 1993, The New England journal of medicine.

[112]  T M Grogan,et al.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[113]  G. Lyman,et al.  Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. , 1993, Journal of the National Cancer Institute.

[114]  H. Gerhartz,et al.  Intervention treatment of established neutropenia with human recombinant granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in patients undergoing cancer chemotherapy. , 1993, Leukemia research.

[115]  J. Wade,et al.  Management of infection in patients with acute leukemia. , 1993, Hematology/oncology clinics of North America.

[116]  K. Propert,et al.  Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. , 1992, The New England journal of medicine.

[117]  L. Hutchins,et al.  Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  I. Tannock,et al.  A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[119]  J. Cooper,et al.  Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. , 1992, The New England journal of medicine.

[120]  E. Estey,et al.  Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia. , 1992, Blood.

[121]  R. Finberg,et al.  Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  J. Crawford,et al.  Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  C. Schiffer,et al.  A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. , 1991, Blood.

[124]  H. Wieand,et al.  Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[125]  L. Fouillard,et al.  GM-CSF instead of autologous bone-marrow transplantation after the BEAM regimen , 1991, The Lancet.

[126]  M. Kris,et al.  Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer , 1991 .

[127]  L. Einhorn,et al.  Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[128]  J. Kahn,et al.  Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[129]  L. Kalish,et al.  Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. , 1991, Transplantation.

[130]  H. Dohy,et al.  Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. , 1990, The New England journal of medicine.

[131]  Anna L. Brown,et al.  Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowe , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[132]  J. Sklar,et al.  Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. , 1990, Blood.

[133]  E. D. de Vries,et al.  Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever. , 1990, European journal of cancer.

[134]  A. Howell,et al.  The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. , 1989, British Journal of Cancer.

[135]  R. Mayer,et al.  The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. , 1988, Archives of internal medicine.

[136]  K. Bhalla,et al.  Effect of recombinant GM-CSF on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells. , 1988, Leukemia.

[137]  J. Gabrilove,et al.  Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. , 1988, The New England journal of medicine.

[138]  E. Douple.  Platinum-radiation interactions. , 1988, NCI monographs : a publication of the National Cancer Institute.

[139]  J. Gutterman,et al.  Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. , 1987, The New England journal of medicine.

[140]  P. Engstrom,et al.  Nonsurgical management of esophageal cancer: report of a study of combined radiotherapy and chemotherapy. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[141]  R. Ginsberg,et al.  Radical radiation therapy with 5-fluorouracil infusion and mitomycin C for oesophageal squamous carcinoma. , 1985, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[142]  J. Suen,et al.  Cisplatin potentiation of radiotherapy. Long-term follow-up. , 1985, Archives of otolaryngology.

[143]  F. Muggia,et al.  Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[144]  B. Barlogie,et al.  Effective treatment of advanced multiple myeloma refractory to alkylating agents. , 1984, The New England journal of medicine.

[145]  Y. S. Sathe,et al.  Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. , 1966, Annals of internal medicine.